ALEC (Alector, Inc.) PDUFA Date | FDA Catalyst & Approval Status

May 7, 2026

▼ -5.1%on this news· ran to -18% by day 1

Alector Reports First Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with

Alector, a biotechnology firm, reported its first quarter 2026 financial results, revealing a cash position of $206.5 million sufficient to fund operations through 2027. The company is actively advancing its Alector Brain Carrier platform, which is involved in various neurodegenerative disease programs, including Alzheimer's and Parkinson's disease therapies. However, it announced the discontinuation of the nivisnebart Phase 2 trial following a futility analysis, and collaboration revenue has decreased compared to the previous year.

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, a

Alector, Inc. reported its fourth quarter and full year 2025 financial results, demonstrating a net loss increase and decreased collaboration revenues compared to 2024. The company highlighted its strong cash position sufficient to fund operations until at least 2027. Progress continues on its Alector Brain Carrier (ABC) platform with candidates targeting Alzheimer's and Parkinson's diseases. An interim futility analysis for the PROGRESS-AD trial is anticipated in 2026, as Alector aims to bring its promising therapies to clinical stage.

Dec 12, 2025

is headquartered in South San Francisco, California. For more information, please visit www.alector.com . Alector Contacts: Argot Partners (media) David Rosen (212) 600-1494 alector@argotpartners.com Argot Partners (inve

Alector, Inc. has appointed Neil Berkley as its Chief Financial Officer effective December 10, 2025. Berkley, who also continues as Chief Business Officer, has been with Alector since March 2024 and has contributed significantly to the company's strategic priorities. Alector is focused on developing therapies for neurodegenerative diseases and leverages a proprietary platform to enhance therapeutic delivery.

Nov 6, 2025

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, an

Alector, Inc. announced its third-quarter financial results, highlighting a focused advancement of its innovative drug candidates aimed at neurodegenerative diseases. The company reported a cash position of $291.1 million and outlined progress on its Alector Brain Carrier platform, including lead candidates AL137 and AL050. Furthermore, the PROGRESS-AD Phase 2 trial for nivisnebart is on track for an interim analysis in the first half of 2026. However, the firm also faced challenges, including a revenue decline and the discontinuation of the latozinemab trial due to lack of clinical benefit, necessitating workforce reductions.

Oct 21, 2025

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

Alector, Inc. announced that the Phase 3 INFRONT-3 trial of latozinemab in treating frontotemporal dementia due to a GRN mutation did not meet its primary clinical endpoint. While the drug showed a statistically significant impact on the biomarker endpoint of plasma progranulin concentrations, overall treatment effects on FTD-GRN were not demonstrated. Consequently, the company will discontinue the open-label extension and continuation study for the drug. Alector is also making significant operational changes, including a workforce reduction, to realign its focus on key research and clinical programs.

Aug 7, 2025

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rar

Alector, Inc. has reported its financial results for the second quarter of 2025, highlighting its focus on neurodegenerative disease therapies. The company's progress includes upcoming topline data from the INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN, expected by mid-Q4 2025. Despite a decline in collaboration revenue, Alector maintains a strong cash position to support ongoing research and development initiatives, including their Phase 2 trial of AL101 in Alzheimer's disease. The company continues to advance its pipeline for neurodegenerative conditions, supported by its proprietary Alector Brain Carrier technology.

Jun 13, 2025

Alector Provides Executive Leadership Update Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective

Alector, Inc. has appointed Neil Berkley, M.B.A., as the Interim Chief Financial Officer, succeeding Marc Grasso, M.D., who is leaving to pursue other opportunities. Berkley, who has over 20 years of experience in corporate and business development, will also retain his current role as Chief Business Officer. Alector anticipates that the company’s financial stability, with a cash runway extending into 2027, will support its ongoing clinical and research programs. The company is on track to report data from key clinical trials by the end of 2025.

May 8, 2025

Alector Reports First Quarter 2025 Financial Results and Provides Business Update Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS

Alector, Inc. reported its financial results for the first quarter of 2025, highlighting significant advancements in its clinical trials for neurodegenerative diseases. The company is on track to release topline data from the INFRONT-3 Phase 3 trial of latozinemab by Q4 2025 and has completed enrollment in the PROGRESS-AD Phase 2 trial. Alector's financial position remains strong, with $354.6 million in cash that supports its ongoing development programs into 2027. However, the company experienced a notable decline in collaboration revenue and an increase in net loss compared to the previous year.

Feb 26, 2025

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate com

Alector, a biotech company, reported its Q4 and full-year 2024 financial results, highlighting a robust cash position of $413.4 million. The company is advancing its clinical programs with key milestones ahead, including topline data from the INFRONT-3 Phase 3 trial of latozinemab expected by Q4 2025 and completion of enrollment in the PROGRESS-AD Phase 2 trial by mid-2025. Alector is also progressing its innovative preclinical pipeline, aiming to deliver therapies for neurodegenerative conditions.

Nov 14, 2024

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital South San Francisco, Calif.

Alector, a clinical-stage biotechnology company, has announced a debt financing agreement with Hercules Capital for up to $50 million. This funding aims to strengthen Alector's financial position and support its preclinical pipeline, including innovative therapies for neurodegenerative diseases. The initial drawdown of $10 million has been completed, with further funding available until 2026. Alector's leadership expresses optimism for upcoming trial results that could significantly impact patient treatment options.

Nov 6, 2024

in Alector's Quarterly Report on Form 10-Q filed on

Alector, Inc. announced the results from its INVOKE-2 Phase 2 clinical trial, which evaluated AL002 for early Alzheimer's disease. The trial results indicated that AL002 did not meet its primary endpoint of slowing disease progression, nor did it show significant effects on secondary endpoints or Alzheimer's biomarkers. As a result, Alector will cease the long-term extension study and reduce its workforce by around 17%. Nevertheless, the company remains committed to developing novel therapeutics for neurodegenerative disorders, backed by substantial financial resources.

Nov 6, 2024

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024 Participan

Alector, Inc. has provided a business update along with its third quarter 2024 financial results, highlighting advancements in their Alzheimer's disease and frontotemporal dementia programs. The company reported a substantial cash position of $457.2 million, enough to fund operations through 2026. Alector is set to present data from the INVOKE-2 Phase 2 trial of its TREM2 candidate AL002 in 2024, while the INFRONT-3 Phase 3 trial for frontotemporal dementia is progressing towards anticipated top-line data in late 2025 or early 2026.

Aug 7, 2024

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024 Patient baseli

Alector, Inc. reported its financial results for the second quarter of 2024, highlighting significant advancements in its drug development pipeline. The company is set to release data from its INVOKE-2 Phase 2 clinical trial for AL002, targeting early Alzheimer's disease, in the fourth quarter. Additionally, Alector's cash reserves of $503.3 million provide a robust financial backing through 2026. Despite a notable decrease in collaboration revenue compared to the previous year, the company remains optimistic due to recent regulatory achievements and its ongoing clinical trials.

May 8, 2024

Alector Reports First Quarter 2024 Financial Results and Provides Business Update Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 20

Alector has reported its first quarter financial results for 2024, maintaining a robust cash position of $562.1 million which is expected to support operations until 2026. The company announced the advancement of its clinical trials for Alzheimer's disease, including the pivotal INVOKE-2 trial, with results anticipated in Q4 2024. Notably, Alector has strengthened its leadership team by appointing experienced executives to drive growth. However, despite these highlights, Alector continues to face significant net losses and fluctuations in collaboration revenue.

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD)

Alector, Inc. reported its fourth quarter and full year 2023 financial results, highlighting significant progress in its clinical programs. The company has completed enrollment for the INVOKE-2 Phase 2 trial of AL002 and the pivotal INFRONT-3 Phase 3 trial of latozinemab. Additionally, the FDA granted Breakthrough Therapy Designation for latozinemab targeting frontotemporal dementia due to a mutation in the progranulin gene. Alector maintains a strong financial position with $620 million expected to fund operations through 2026.

Jan 17, 2024

▼ -14%on this news· ran to -24% by day 1

Alector Announces Pricing of Public Offering of Common Stock South San Francisco, Calif.

Alector, Inc. has announced the pricing of a public offering of 10,869,566 shares of common stock, aiming to raise total gross proceeds of $75 million before deductions. The offering is set to close on January 19, 2024, subject to customary closing conditions. All shares in the offering are being sold by Alector, with Fitzgerald & Co. acting as the book-running manager. This move reflects Alector's ongoing commitment to financing its innovative immuno-neurology programs targeting neurodegenerative diseases.

Nov 7, 2023

▲ +5.1%on this news· ran to -18% by day 3

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants Enrol

Alector has reported its third quarter 2023 financial results alongside updates on clinical trials, including key milestones in its immuno-neurology programs. The company successfully completed enrollment in the pivotal INFRONT-3 Phase 3 trial with 103 symptomatic participants and the INVOKE-2 Phase 2 trial in early Alzheimer's disease, with data readout expected in 2024. Alector's financial standing remains solid with $588.9 million available, supporting operations through 2025 despite a net loss of $44.5 million this quarter.

Aug 3, 2023

Alector Reports Second Quarter 2023 Financial Results and Provides Business Update Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer's disease; completing enrollment in Q3 2023,

Alector, Inc. reported its second quarter 2023 financial results and business updates, highlighting the closure of screening in the INVOKE-2 Phase 2 trial for AL002 targeting early Alzheimer's disease. The company anticipates completing enrollment in this trial by Q3 2023 and expects data readout in Q4 2024. Additionally, Alector's strong cash position of $630 million will support operations through 2025. While revenue saw a decrease compared to the prior year, positive outcomes from regulatory interactions and advancements in their pipeline efforts were emphasized.

May 4, 2023

Alector Reports First Quarter 2023 Financial Results and Provides Business Update On track to engage with regulatory authorities on the pivotal Phase 3 INFRONT-3 clinical trial of latozinemab in mid-2023; targeting data

Alector, a clinical-stage biotechnology company, reported its financial results for Q1 2023 and provided updates on its clinical programs. The company is on track to engage with regulatory authorities regarding the Phase 3 INFRONT-3 trial of latozinemab in mid-2023, targeting data readout by early 2025. Alector also anticipates completing enrollment in the INVOKE-2 Phase 2 trial by Q3 2023. Despite a reported net loss of $45.9 million, Alector's strong cash position of $669.3 million supports ongoing operations through 2025.

Feb 28, 2023

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer's disease

Alector, Inc. reported its fourth quarter and full year 2022 financial results, providing a corporate update on its clinical trials and financial status. The company is on track to complete enrollment in the INVOKE-2 Phase 2 clinical trial for AL002 in early Alzheimer's disease by Q3 2023, with data readout anticipated in Q4 2024. Alector's cash reserves amount to $712.9 million, ensuring a runway through 2025. They also plan to advance their AL101 program in collaboration with GSK, targeting a pivotal data readout from the INFRONT-3 trial for late-stage dementia in early 2025.

Nov 8, 2022

Alector Reports Third Quarter 2022 Financial Results and Provides Business Update Progressing enrollment in the INFRONT-3 Phase 3 pivotal study for latozinemab (AL001) and in the INVOKE-2 Phase 2 study for AL002 Initiate

Alector Reports Third Quarter 2022 Financial Results and Provides Business Update Progressing enrollment in the INFRONT-3 Phase 3 pivotal study for latozinemab (AL001) and in the INVOKE-2 Phase 2 study for AL002 Initiated first-in-human Phase 1 trial of AL044, the company's thi

Aug 4, 2022

Alector Reports Second Quarter 2022 Financial Results and Provides Business Update Investigational New Drug Application submitted for AL044, a novel drug candidate targeting an Alzheimer's disease risk gene Expanding cli

Alector Reports Second Quarter 2022 Financial Results and Provides Business Update Investigational New Drug Application submitted for AL044, a novel drug candidate targeting an Alzheimer's disease risk gene Expanding clinical sites to drive additional enrollment in the INFRONT-

May 5, 2022

▼ -6.7%on this news· ran to -20% by day 3

Alector Reports First Quarter 2022 Financial Results and Provides Business Update Data from INFRONT-2 Phase 2 clinical trial showed that FTD-C9orf72 patients treated with AL001 (latozinemab) demonstrated a trend towards

Alector Reports First Quarter 2022 Financial Results and Provides Business Update Data from INFRONT-2 Phase 2 clinical trial showed that FTD-C9orf72 patients treated with AL001 (latozinemab) demonstrated a trend towards an annual delay in disease progression of approximately 54

Mar 29, 2022

Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer South San Francisco, Calif.

Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer South San Francisco, Calif., March 29, 2022 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.

Feb 24, 2022

ALECConferences/Events

Alector Reports Fourth Quarter and Full Year 2021 Financial Results CTAD and SITC presentations in fourth quarter highlight progress across immuno-neurology and immuno-oncology portfolio Over $900 million in pro forma

Alector Reports Fourth Quarter and Full Year 2021 Financial Results CTAD and SITC presentations in fourth quarter highlight progress across immuno-neurology and immuno-oncology portfolio Over $900 million in pro forma cash, cash equivalents and investments supports execution o

Feb 7, 2022

Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer South San Francisco, Calif.

Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer South San Francisco, Calif., February 7, 2022 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today a

Nov 4, 2021

Alector Reports Third Quarter 2021 Financial Results Initiated Phase 2 Clinical Trial of AL001 for the Treatment of Amyotrophic Lateral Sclerosis Executed a Global Collaboration with GSK to Co-development and Co-commerci

Alector Reports Third Quarter 2021 Financial Results Initiated Phase 2 Clinical Trial of AL001 for the Treatment of Amyotrophic Lateral Sclerosis Executed a Global Collaboration with GSK to Co-development and Co-commercialize Alector's Progranulin Franchise Molecules for the Tr

Sep 28, 2021

Alector Announces Appointment of Elizabeth A. Garofalo, M.D., to its Board of Directors South San Francisco, Calif.

Alector Announces Appointment of Elizabeth A. Garofalo, M.D., to its Board of Directors Francisco, Calif., September 28, 2021 Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. G

Sep 7, 2021

Alector Provides Executive Leadership Update Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer Sa

Alector Provides Executive Leadership Update Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer Sam Jackson, M.D., MBA, Appointed Interim Chief Medical Officer South S

Aug 3, 2021

Alector Reports Second Quarter 2021 Financial Results Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer's Association International Conference (AAIC) Announced globa

Alector Reports Second Quarter 2021 Financial Results Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer's Association International Conference (AAIC) Announced global collaboration with GSK to co-develop and co-commercializ

Jul 29, 2021

▼ -21.1%on this newsshared move

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation AL001 Successfully Restored Pr

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients Treatment w

Jul 7, 2021

For media and investors only Issued: 7:30AM ET, 2 July 2021, London UK Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neuro

For media and investors only Issued: 7:30AM ET, 2 July 2021, London UK GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYS

May 5, 2021

Media 1AB Dan Budwick 973-271-6085 dan@1abmedia.com or Investors: Alector, Inc. ir@alector.com

Alector Reports 2021 First Quarter Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., May 5, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced business updates and f

Feb 25, 2021

Media Erica Jefferson Vice President, Communications and Public Affairs Alector, Inc. 301-928-4650 erica.jefferson@alector.com 1AB Dan Budwick 973-271-6085 dan@1abmedia.com or Investors: Alector, Inc. ir@alector

Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced business updates and f

Jan 20, 2021

Alector Announces Departure of Chief Business Officer Sabah Oney steps down as from a role held since January 2018; joined Alector in October 2016 The departure will be effective

Alector Announces Departure of Chief Business Officer SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that chief business officer (CBO), Sabah Oney, Ph.D., will be lea

Nov 10, 2020

Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Global Phase 3 INFRONT-3 trial evaluating AL001 for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) c

Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates a

Aug 11, 2020

Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update - Pivotal Phase 3 trial of AL001 initiated for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) - Promi

Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and financial res

May 13, 2020

Alector Reports 2020 First Quarter Financial Results and Business Highlights • Provides business continuity update regarding COVID-19 • Continued execution across immuno-neurology platform • On track

Alector Reports 2020 First Quarter Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., May 13, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical- stage biotechnology company pioneering immuno-neurology, today announced business highlights and financial results

Mar 24, 2020

Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business Highlights • Continued execution across immuno-neurology platform, with multiple clinical, regulatory and operational milestones ach

Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., March 24, 2020 -- Alector, Inc. (Nasdaq: ALEC), a clinical- stage biotechnology company pioneering immuno-neurology, today announced company highlights and fi

Feb 3, 2020

Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Total gross proceeds from the offering to Alector are approximately $240 million

Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif. February 3, 2020 Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, to

Dec 13, 2019

Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D Day - Reported results from analysis of the Phase 1b study of AL001 in patients with symptomatic FTD-GRN showing a statistica

Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D Day SOUTH SAN FRANCISCO, Calif., Dec. 13, 2019 -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it will provide

Nov 12, 2019

Alector Reports Recent Business Highlights and Third Quarter 2019 Financial Results - Initiated AL001 Phase 2 clinical study and dosed multiple frontotemporal dementia patients with a progranulin mutation (FTD-GRN) or a

Alector Reports Recent Business Highlights and Third Quarter 2019 Financial Results SOUTH SAN FRANCISCO, Calif. - November 12, 2019 - Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced Company highlights and financia

Aug 12, 2019

Alector Reports Recent Business Highlights and Second Quarter 2019 Financial Results - Completed planned enrollment of AL001 Phase 1b trial and demonstrated proof-of-mechanism in Frontotemporal Dementia patients - AL101

Alector Reports Recent Business Highlights and Second Quarter 2019 Financial Results SOUTH SAN FRANCISCO, Calif. - August 12, 2019 - Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced company highlights and financial

Aug 12, 2019

Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors South San Francisco, Calif.

Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors South San Francisco, Calif. - August 12, 2019 - Alector, Inc. (Nasdaq: ALEC) today announced the addition of Kristine Yaffe, M.D., to the Company's board of directors. Dr. Yaffe is the Scola Endowe

May 13, 2019

Alector Reports Recent Business Highlights and First Quarter 2019 Financial Results - Dosed first frontotemporal dementia patient with AL001 in the Phase 1b portion of the INFRONT clinical study - Dosed first Alzheimer's

Alector Reports Recent Business Highlights and First Quarter 2019 Financial Results South San Francisco, Calif. - May 13, 2019 - Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of ne

Mar 26, 2019